Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6879221 | 0.84 | PBRM1 (0.54) | L3MBTL1SLC6A4IDO1HTR6F7 | |
| SCHEMBL1434181 | 0.83 | F7 (0.58) | SLC6A4IDO1HTR6F7F3 | |
| SCHEMBL6631032 | 0.82 | GABRA1 (0.48) | L3MBTL1SLC6A4IDO1 | |
| SCHEMBL3631475 | 0.81 | ALDH1A1 (0.54) | L3MBTL1SLC6A4IDO1HTR6F7 | |
| SCHEMBL9937045 | 0.80 | NR4A2 (0.65) | SLC6A4 | |
| SCHEMBL7464145 | 0.79 | SLC6A4 (0.49) | SLC6A4HTR6SLC6A2SLC6A3HTR1A | |
| SCHEMBL7386532 | 0.78 | IDO1 (0.43) | L3MBTL1SLC6A4IDO1HTR6F7 | |
| SCHEMBL12782163 | 0.78 | F7 (0.45) | SLC6A4IDO1HTR6F7F3 | |
| SCHEMBL8808423 | 0.78 | LMNA (0.62) | SLC6A4IDO1HTR6F7F3 | |
| SCHEMBL2076915 | 0.78 | IDO1 (0.46) | SLC6A4IDO1HTR6SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | TRIM33, TRIM28, TRIM4 | L3MBTL1 487/4885SLC6A4 4588/4885IDO1 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.